| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Section of Medical Oncology, Department of Medicine and Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06520-8032
In this study, we report the occurrence of missense mutations of the transforming growth factor ß (TGFß) type II receptor gene in two human squamous head and neck carcinoma cell lines. Both mutations are G:C
C:G transversions, which result in the replacement of a glutamic acid by a glutamine, and of an arginine by a proline residue, respectively. Moreover, both are located at highly conserved sites within the serine-threonine kinase domain. One of the mutants appears to be defective in its autophosphorylation as well as in the transphosphorylation of the TGFß type I receptor protein, whereas the second mutant appears to be constitutively activated. These are the first reported naturally occurring nucleotide substitution mutations in the TßR-II gene in human head and neck cancer cells, which may explain their resistance to TGFß1-mediated cell cycle arrest.
1 Supported in part by USPHS Award CA41556 (to M. R.) from the National Cancer Institute (including a Supplement for Underrepresented Minorities to Grant CA41556 from the National Cancer Institute to T. M. A.) and by a fellowship grant from the French Association pour la Recherche sur le Cancer (L. G-A.).
2 L. G-A. and T. M-A. contributed in equal measure to the design and execution of this project.
3 Present address: H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612-9497.
4 To whom requests for reprints should be addressed, at Section of Medical Oncology, Room NS 291 (SHM), Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8032.
Received 7/11/95. Accepted 8/ 4/95.
This article has been cited by other articles:
|
|
 |
|
  S. Tchatchou, A. Jung, K. Hemminki, C. Sutter, B. Wappenschmidt, P. Bugert, B. H.F. Weber, D. Niederacher, N. Arnold, R. Varon-Mateeva, et al. A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women Carcinogenesis, January 1, 2009; 30(1): 59 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bharathy, W. Xie, J. M. Yingling, and M. Reiss Cancer-Associated Transforming Growth Factor {beta} Type II Receptor Gene Mutant Causes Activation of Bone Morphogenic Protein-Smads and Invasive Phenotype Cancer Res., March 15, 2008; 68(6): 1656 - 1666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Chen, P. Ghosh, H. Osawa, C. Y. Sasaki, L. Rezanka, J. Yang, T. J. O'Farrell, and D. L. Longo Resistance to TGF-{beta}1 correlates with aberrant expression of TGF-{beta} receptor II in human B-cell lymphoma cell lines Blood, June 15, 2007; 109(12): 5301 - 5307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-L. Lu, H. Herrington, D. Reh, S. Weber, S. Bornstein, D. Wang, A. G. Li, C.-F. Tang, Y. Siddiqui, J. Nord, et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes & Dev., May 15, 2006; 20(10): 1331 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pasche, T. J. Knobloch, Y. Bian, J. Liu, S. Phukan, D. Rosman, V. Kaklamani, L. Baddi, F. S. Siddiqui, W. Frankel, et al. Somatic Acquisition and Signaling of TGFBR1*6A in Cancer JAMA, October 5, 2005; 294(13): 1634 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Baez, A. Cantor, S. Fonseca, M. Marcos-Martinez, L. A. Mathews, C. A. Muro-Cacho, and T. Munoz-Antonia Differences in Smad4 Expression in Human Papillomavirus Type 16-Positive and Human Papillomavirus Type 16-Negative Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., May 1, 2005; 11(9): 3191 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.S. Prime, M. Davies, M. Pring, and I.C. Paterson THE ROLE OF TGF-{beta} IN EPITHELIAL MALIGNANCY AND ITS RELEVANCE TO THE PATHOGENESIS OF ORAL CANCER (PART II) Critical Reviews in Oral Biology & Medicine, November 1, 2004; 15(6): 337 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Kaklamani, N. Hou, Y. Bian, J. Reich, K. Offit, L. S. Michel, W.S. Rubinstein, A. Rademaker, and B. Pasche TGFBR1*6A and Cancer Risk: A Meta-Analysis of Seven Case-Control Studies J. Clin. Oncol., September 1, 2003; 21(17): 3236 - 3243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Hempen, L. Zhang, R. K. Bansal, C. A. Iacobuzio-Donahue, K. M. Murphy, A. Maitra, B. Vogelstein, R. H. Whitehead, S. D. Markowitz, J. K. V. Willson, et al. Evidence of Selection for Clones Having Genetic Inactivation of the Activin A Type II Receptor (ACVR2) Gene in Gastrointestinal Cancers Cancer Res., March 1, 2003; 63(5): 994 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Flanders and J. K. Burmester Medical Applications of Transforming Growth Factor-{beta} Clin. Med. Res., January 1, 2003; 1(1): 13 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hamamoto, H. Beppu, H. Okada, M. Kawabata, T. Kitamura, K. Miyazono, and M. Kato Compound Disruption of Smad2 Accelerates Malignant Progression of Intestinal Tumors in Apc Knockout Mice Cancer Res., October 15, 2002; 62(20): 5955 - 5961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Adnane, E. Seijo, Z. Chen, F. Bizouarn, M. Leal, S. M. Sebti, and T. Munoz-Antonia RhoB, Not RhoA, Represses the Transcription of the Transforming Growth Factor beta Type II Receptor by a Mechanism Involving Activator Protein 1 J. Biol. Chem., March 1, 2002; 277(10): 8500 - 8507. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yagi, M. Furuhashi, H. Aoki, D. Goto, H. Kuwano, K. Sugamura, K. Miyazono, and M. Kato c-myc Is a Downstream Target of the Smad Pathway J. Biol. Chem., January 4, 2002; 277(1): 854 - 861. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. M. Bruckheimer and N. Kyprianou Dihydrotestosterone Enhances Transforming Growth Factor-{beta}-Induced Apoptosis in Hormone-Sensitive Prostate Cancer Cells Endocrinology, June 1, 2001; 142(6): 2419 - 2426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Chen, J. Triplett, B. Dehner, B. Hurst, B. Colligan, J. Pemberton, J. R. Graff, and J. H. Carter Transforming Growth Factor-{beta} Receptor Type I Gene Is Frequently Mutated in Ovarian Carcinomas Cancer Res., June 1, 2001; 61(12): 4679 - 4682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Muro-Cacho, K. Rosario-Ortiz, S. Livingston, and T. Munoz-Antonia Defective Transforming Growth Factor {beta} Signaling Pathway in Head and Neck Squamous Cell Carcinoma as Evidenced by the Lack of Expression of Activated Smad2 Clin. Cancer Res., June 1, 2001; 7(6): 1618 - 1626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Franchi, O Gallo, I Sardi, and M Santucci Downregulation of transforming growth factor {beta} type II receptor in laryngeal carcinogenesis J. Clin. Pathol., March 1, 2001; 54(3): 201 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Tobin, M. K. Brown, K. Douville, D. C. Payne, A. Eastman, and B. A. Arrick Inhibition of Transforming Growth Factor {beta} Signaling in MCF-7 Cells Results in Resistance to Tumor Necrosis Factor {{alpha}}: A Role for Bcl-2 Cell Growth Differ., February 1, 2001; 12(2): 109 - 117. [Abstract] [Full Text]
|
|
|
|
|
|
C. D. Lücke, A. Philpott, J. C. Metcalfe, A. M. Thompson, L. Hughes-Davies, P. R. Kemp, and R. Hesketh Inhibiting Mutations in the Transforming Growth Factor {beta} Type 2 Receptor in Recurrent Human Breast Cancer Cancer Res., January 1, 2001; 61(2): 482 - 485. [Abstract] [Full Text]
|
|
|
|
|
|
J. L. Schwartz Biomarkers and Molecular Epidemiology and Chemoprevention of Oral Carcinogenesis Critical Reviews in Oral Biology & Medicine, January 1, 2000; 11(1): 92 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pasche, P. Kolachana, K. Nafa, J. Satagopan, Y.-G. Chen, R. S. Lo, D. Brener, D. Yang, L. Kirstein, C. Oddoux, et al. T{{beta}}R-I(6A) Is a Candidate Tumor Susceptibility Allele Cancer Res., November 1, 1999; 59(22): 5678 - 5682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tokunaga, D.-H. Lee, I. Y. Kim, T. M. Wheeler, and S. P. Lerner Decreased Expression of Transforming Growth Factor {beta} Receptor Type I Is Associated with Poor Prognosis in Bladder Transitional Cell Carcinoma Patients Clin. Cancer Res., September 1, 1999; 5(9): 2520 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Muro-Cacho, M. Anderson, J. Cordero, and T. Munoz-Antonia Expression of Transforming Growth Factor {beta} Type II Receptors in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., June 1, 1999; 5(6): 1243 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Guo and N. Kyprianou Restoration of Transforming Growth Factor {beta} Signaling Pathway in Human Prostate Cancer Cells Suppresses Tumorigenicity via Induction of Caspase-1-mediated Apoptosis Cancer Res., March 1, 1999; 59(6): 1366 - 1371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. M. Grady, L. L. Myeroff, S. E. Swinler, A. Rajput, S. Thiagalingam, J. D. Lutterbaugh, A. Neumann, M. G. Brattain, J. Chang, S.-J. Kim, et al. Mutational Inactivation of Transforming Growth Factor {beta} Receptor Type II in Microsatellite Stable Colon Cancers Cancer Res., January 1, 1999; 59(2): 320 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wu, R. S. Fan, W. Li, V. Srinivas, and M. G. Brattain Regulation of Transforming Growth Factor-beta Type II Receptor Expression in Human Breast Cancer MCF-7 Cells by Vitamin D3 and Its Analogues J. Biol. Chem., March 27, 1998; 273(13): 7749 - 7756. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Li, S. M. Karam, K. A. Coerver, M. M. Matzuk, and J. I. Gordon Stimulation of Activin Receptor II Signaling Pathways Inhibits Differentiation of Multiple Gastric Epithelial Lineages Mol. Endocrinol., February 1, 1998; 12(2): 181 - 192. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. R. Amoroso, N. Huang, A. B. Roberts, M. Potter, and J. J. Letterio Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas PNAS, January 6, 1998; 95(1): 189 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. DeCoteau, P. I. Knaus, H. Yankelev, M. D. Reis, R. Lowsky, H. F. Lodish, and M. E. Kadin Loss of functional cell surface transforming growth factor beta (TGF-beta ) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia PNAS, May 27, 1997; 94(11): 5877 - 5881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Wang, D. A. Greenhalgh, J. R. Bickenbach, A. Jiang, D. S. Bundman, T. Krieg, R. Derynck, and D. R. Roop Expression of a dominant-negative type II transforming growth factor beta (TGF-beta ) receptor in the epidermis of transgenic mice blocks TGF-beta -mediated growth inhibition PNAS, March 18, 1997; 94(6): 2386 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamada, K. Vijayachandra, C. Penner, and A. Glick Increased Sensitivity of Transforming Growth Factor (TGF) beta 1 Null Cells to Alkylating Agents Reveals a Novel Link between TGFbeta Signaling and O6-Methylguanine Methyltransferase Promoter Hypermethylation J. Biol. Chem., May 25, 2001; 276(22): 19052 - 19058. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
